Literature DB >> 29369669

Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement.

Daniel Fulford1, Michael Treadway2, Joshua Woolley3.   

Abstract

Experiential negative symptoms-including diminished motivation-have a profound impact on functional outcomes in schizophrenia. Animal research suggests that abnormalities in dopaminergic regulation can negatively impact effort exertion, a translational model that has been applied to individuals with schizophrenia. Paradigms that assess effort-based decision making, for example, suggest less likelihood of choosing high effort tasks that are high in probability of success, and this preference varies with negative symptoms and impaired functioning. Although asociality is another well-documented component of experiential negative symptoms, it is unclear whether diminished motivation for monetary reward extends to the social domain. To test this question, the authors designed the Social Vigor Task (SVT)-a measure of effort exertion in the context of live social encouragement. They further examined the effect of oxytocin, a neuropeptide implicated in social behavior, on vigor. Forty-two individuals with schizophrenia and 43 healthy controls completed the SVT twice: once after intranasal administration of saline placebo and again after oxytocin. Both groups showed similar increases in vigor in response to social encouragement, suggesting effort in the social context is spared in schizophrenia. Group differences in the effect of social encouragement on vigor varied by point-based reward rate and trial length. Oxytocin did not increase vigor during social encouragement in either group. Within the schizophrenia group, clinician-rated passive social withdrawal, but not active social avoidance, was negatively associated with vigor. Results suggest that people with schizophrenia show normative levels of effort in the context of social encouragement; low approach motivation, however, relates to lower effort. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29369669      PMCID: PMC7446385          DOI: 10.1037/abn0000320

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  83 in total

Review 1.  The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis.

Authors:  Anne-Kathrin J Fett; Wolfgang Viechtbauer; Maria-de-Gracia Dominguez; David L Penn; Jim van Os; Lydia Krabbendam
Journal:  Neurosci Biobehav Rev       Date:  2010-07-08       Impact factor: 8.989

Review 2.  The mysterious motivational functions of mesolimbic dopamine.

Authors:  John D Salamone; Mercè Correa
Journal:  Neuron       Date:  2012-11-08       Impact factor: 17.173

3.  Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.

Authors:  Daimei Sasayama; Kotaro Hattori; Toshiya Teraishi; Hiroaki Hori; Miho Ota; Sumiko Yoshida; Kunimasa Arima; Teruhiko Higuchi; Naoji Amano; Hiroshi Kunugi
Journal:  Schizophr Res       Date:  2012-06-27       Impact factor: 4.939

4.  Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

Authors:  J D Woolley; B Chuang; C Fussell; S Scherer; B Biagianti; D Fulford; D H Mathalon; S Vinogradov
Journal:  Psychol Med       Date:  2017-01-16       Impact factor: 7.723

5.  Do people with schizophrenia have difficulty anticipating pleasure, engaging in effortful behavior, or both?

Authors:  David E Gard; Amy H Sanchez; Kathryn Cooper; Melissa Fisher; Coleman Garrett; Sophia Vinogradov
Journal:  J Abnorm Psychol       Date:  2014-08-18

6.  Sex differences in hormonal modulation of anxiety measured with light-enhanced startle: possible role for arginine vasopressin in the male.

Authors:  Donna Toufexis; Carrie Davis; Alexis Hammond; Michael Davis
Journal:  J Neurosci       Date:  2005-09-28       Impact factor: 6.167

Review 7.  Social effects of oxytocin in humans: context and person matter.

Authors:  Jennifer A Bartz; Jamil Zaki; Niall Bolger; Kevin N Ochsner
Journal:  Trends Cogn Sci       Date:  2011-06-21       Impact factor: 20.229

8.  The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study.

Authors:  Josh D Woolley; Peter A Arcuni; Christopher S Stauffer; Daniel Fulford; Dean S Carson; Steve Batki; Sophia Vinogradov
Journal:  Psychopharmacology (Berl)       Date:  2016-05-03       Impact factor: 4.530

9.  Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia.

Authors:  David E Gard; Melissa Fisher; Coleman Garrett; Alexander Genevsky; Sophia Vinogradov
Journal:  Schizophr Res       Date:  2009-09-23       Impact factor: 4.939

10.  Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.

Authors:  D Glovinsky; K T Kalogeras; D G Kirch; R Suddath; R J Wyatt
Journal:  Schizophr Res       Date:  1994-02       Impact factor: 4.939

View more
  3 in total

1.  Are Negative Symptoms Merely the "Real World" Consequences of Deficits in Social Cognition?

Authors:  Andrea Pelletier-Baldelli; Daphne J Holt
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

2.  Anhedonia in Schizophrenia.

Authors:  Erin K Moran; Adam J Culbreth; Deanna M Barch
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.

Authors:  Kah Kheng Goh; Chun-Hsin Chen; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.